Pharmacogenetic variants and treatment-related toxicity during consolidation therapy in a child with Down syndrome-associated acute lymphoblastic leukemia: a case report

Background

Children with Down syndrome-associated acute lymphoblastic leukemia (DS-ALL) are vulnerable to chemotherapy-related toxicity, including methotrexate toxicity. Pharmacogenetic variation in folate and methotrexate pathway genes may contribute to interindividual variability, but evidence in DS-ALL remains limited.